5-bromo-1-(difluoromethyl)-3-methylpyridin-2(1H)-one | 1556472-90-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-1-(difluoromethyl)-3-methylpyridin-2(1H)-one
• 英文别名: 5-Bromo-1-(difluoromethyl)-3-methyl-1,2-dihydropyridin-2-one；5-bromo-1-(difluoromethyl)-3-methylpyridin-2-one
• CAS: 1556472-90-2
• 化学式: C₇H₆BrF₂NO
• 分子量: 238.032
• InChiKey: QHASDTVBBDEWKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丙醇 、 一氧化碳 、 5-bromo-1-(difluoromethyl)-3-methylpyridin-2(1H)-one 在 1,1'-bis(diphenylphosphino)ferrocene 、 palladium diacetate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 n-propyl 1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate
  参考文献：
  名称：

  Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor

  摘要：

  A series of 2-pyridone-containing imidazoline derivatives was synthesized and evaluated as neuropeptide Y Y5 receptor antagonists. Optimization of the 2-pyridone structure on the 2-position of the imidazoline ring led to identification of 1-(difluoromethyl)-5-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoropyridin- 3-yl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl] pyridin-2(1H)-one (7m). Compound 7m displayed statistically significant inhibition of food intake in an agonist-induced food intake model in SD rats and no adverse cardiovascular effects in anesthetized dogs. In addition, markedly higher brain penetrability and a lower plasma Occ90 value were observed in P-gp-deficient mdr1a (-/-) mice compared to mdr1a (+/+) mice after oral administration of 7m. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.069
• 作为产物：
  描述：

  sodium chlorodifluoroacetate 、 2-羟基-3-甲基-5-溴吡啶 在 sodium hydride 、 lithium bromide 作用下， 以 N,N-二甲基甲酰胺 、 oil 为溶剂， 反应 0.5h， 以870 mg的产率得到5-bromo-1-(difluoromethyl)-3-methylpyridin-2(1H)-one
  参考文献：
  名称：

  Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor

  摘要：

  A series of 2-pyridone-containing imidazoline derivatives was synthesized and evaluated as neuropeptide Y Y5 receptor antagonists. Optimization of the 2-pyridone structure on the 2-position of the imidazoline ring led to identification of 1-(difluoromethyl)-5-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoropyridin- 3-yl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl] pyridin-2(1H)-one (7m). Compound 7m displayed statistically significant inhibition of food intake in an agonist-induced food intake model in SD rats and no adverse cardiovascular effects in anesthetized dogs. In addition, markedly higher brain penetrability and a lower plasma Occ90 value were observed in P-gp-deficient mdr1a (-/-) mice compared to mdr1a (+/+) mice after oral administration of 7m. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.069

文献信息

• [EN] 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE<br/>[FR] DÉRIVÉS D'AMINO TRIAZOLO QUINAZOLINE À SUBSTITUTION EN POSITIONS 7, 8 ET 10 UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2020112706A1

  公开（公告）日：2020-06-04

  In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  在其多种实施方式中，本发明提供了某些7-、8-和10-取代氨基三唑喹唑啉衍生物的化合物（I）的制备方法和用途，或其药学上可接受的盐，其中环A、R1、R2和R4如本文所定义，包括一种或多种这样的化合物的药物组合物（单独使用和与一种或多种其他治疗剂联合使用），以及其制备和用途的方法，单独使用和与其他治疗剂联合使用，作为A2a和/或A2b受体的拮抗剂，并且它们在治疗由腺苷A2a受体和/或腺苷A2b受体至少部分介导的各种疾病、症状或紊乱中的用途。
• 7-, 8-, AND 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3887377A1

  公开（公告）日：2021-10-06